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DSSCarrageenan, a sulfated polysaccharide that is widely used as a food additive, induces inﬂammatory re-
sponses in animal models and human cells. The carrageenan-induced inﬂammatory cascades involve toll-
like receptor (TLR)4- and B-cell leukemia/lymphoma (BCL)10-dependent activation of NF-κB, leading to in-
creased IL-8 production. Translocations involving BCL10 in the mucosa-associated lymphoid tissue (MALT)
lymphomas are associated with constitutive activation of NF-κB. This report presents a mechanism by
which carrageenan exposure leads to prolonged activation of both BCL10 and NF-κB in human colonic epithe-
lial cells. Study ﬁndings demonstrate that nuclear RelA and RelB bind to an NF-κB binding motif in the BCL10
promoter in human colonic epithelial NCM460 and HT-29 cells. In vitro oligonucleotide binding assay, non-
radioactive gel shift assay, and chromatin immunoprecipitation (ChIP) indicate binding of RelA and RelB to
the BCL10 promoter. Prolonged inﬂammation follows activation of the BCL10-NFκB inﬂammatory loop in re-
sponse to carrageenan, shown by increased BCL10, RelA, and IL-8 for 36 to 48 h and increased RelB for 24 h
following withdrawal of carrageenan after 12 h. In contrast, exposure to dextran sulfate sodium, which
does not cause inﬂammation through TLR4 and BCL10 in the colonic epithelial cells, did not provoke pro-
longed activation of inﬂammation. The carrageenan-enhanced BCL10 promoter activity was blocked by
caffeic acid phenethyl ester (CAPE) and MB-132 which inhibit NF-κB activation. These results indicate that
NF-κB binding to the BCL10 promoter can lead to prolonged activation of the carrageenan-induced inﬂamma-
tory cascade by a transcriptional mechanism involving an NF-κB‐BCL10 loop.
Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
1.1. Background about carrageenan exposure
Carrageenans are highly sulfated polysaccharides that are ob-
tained from red seaweeds (Rhodophycae). They have been widely
used for decades as a thickener, stabilizer, or emulsifying agent in10; CAPE, caffeic phenethyl
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C BY-NC-ND license.many processed foods in the Western diet, including dairy products,
processed meats, soymilk, and infant formula, and are also used in a
variety of other products, such as cosmetics, toothpaste, room de-
odorizers, and pharmaceuticals. Current data suggest an average con-
sumption of 250 mg/day of carrageenan in the United States. Multiple
studies in mammals have demonstrated that carrageenan exposure
predictably causes inﬂammation, including development of ulcera-
tions, polyps, colitis, and colorectal tumors, and carrageenan has
been used in thousands of cell-based and animal experiments to
cause inﬂammation, primarily to study mediators of inﬂammation
and anti-inﬂammatory therapeutics [1–3].
1.2. Carrageenan stimulates TLR4‐BCL10 mediated pathway
of inﬂammation
In human colonic epithelial cells and murine models, we have
reported that carrageenan triggers innate immune pathways of in-
ﬂammation in which TLR4 and BCL10 are critical [4–8]. The in-
ﬂammatory response initiated by carrageenan exposure activated
both canonical, involving RelA (p65) and p50, and non-canonical, in-
volving RelB and p52, pathways of NF-κB activation. We have
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via three cascades: 1) a TLR4, BCL10, IkappaB kinase (IKK)γ, and
phospho-IκBα-mediated activation of RelA; 2) a TLR4, BCL10,
phospho-NF-κB-inducing kinase (NIK), IKKα-mediated activation
of the non-canonical pathway leading to nuclear translocation of
p52 and RelB; and 3) a reactive oxygen species (ROS)-mediated
pathway requiring Hsp27 and IKKβ (Fig. 1) [4–8]. Recent work
also demonstrated that carrageenan-induced inﬂammation caused
glucose intolerance, insulin resistance, and impaired insulin signal-
ing in mouse and cell-based studies [9]. These effects are consistent
with the role of TLR4-induced inﬂammation reported in diabetes
and carrageenan stimulation of TLR4-mediated inﬂammatory cas-
cades [10].
1.3. BCL10 is associated with constitutive activation of NF-κB in the
MALT lymphomas
BCL10, which encodes a cytosolic protein composed of 233
amino acids, has a pivotal role in the innate immune-mediated
pathways of inﬂammation that require TLR4. The BCL10 gene
(locus 1p22) was originally identiﬁed from a recurrent breakpoint
t(1;14)(p22;q32) found in gastric mucosa-associated lymphoid tis-
sue (MALT) lymphomas that was associated with constitutive acti-
vation of NF-κB [11,12]. BCL10 was shown to be an adaptor
protein that mediated canonical NF-κB signaling in T and B lympho-
cytes. Subsequently, a critical role for BCL10 in non-myeloid cells
was identiﬁed, including mediation of the inﬂammatory cascade in
response to carrageenan, lipopolysaccharide, platelet-activating fac-
tor (PAF), lysophosphatidic acid, and angiotensin II [4,13–17]. Ex-
periments with BCL10 silencing and mutation in human colonic
epithelial cells demonstrated a requirement for BCL10 in the pro-
duction of canonical and non-canonical activation of NF-κB, involv-
ing NF-κB components RelA and RelB, respectively [6,7,18]. In this
report, we present a transcriptional mechanism by which carra-
geenan initiates an inﬂammatory loop, involving the up-regulationFig. 1. Schematic illustration of carrageenan-stimulated inﬂammatory signaling path-
ways in human colonocytes. Schematic illustration indicates the presence of a signaling
loop following exposure to carrageenan. Carrageenan through TLR4 and BCL10 leads to
nuclear translocation/activation of NF-κB, both RelA and RelB. In turn, these nuclear
factors bind to the putative NF-κB binding element in the BCL10 promoter, stimulating
increased expression of BCL10, which again leads to increased nuclear translocation/
activation of NF-κB through effects on the IKK signalosome.of BCL10 expression and prolonged activation of canonical and
non-canonical NF-κB pathways of inﬂammation. This transcriptional
effect is based on our previous identiﬁcation of a putative NF-κB
binding sequence in the BCL10 promoter that was activated follow-
ing exposure to PAF [17].
2. Materials and methods
2.1. Cell culture of colonic epithelial cells
NCM460 cells, a human colonic epithelial cell line derived from
normal colonic mucosa, were grown in M3:10™ media (INCELL,
San Antonio, TX) and maintained at 37 °C in a humidiﬁed 5%CO2 en-
vironment with media changes at 2-day intervals [19]. The HT-29
(ATCC #HTB-38) cell line, a human colonic adenocarcinoma cell
line, was grown in DMEM media with 10% FBS.
2.2. BCL10 promoter activity by luciferase assay
A 1310 bp promoter region of BCL10 gene (NM_003921) that was
cloned previously into pGL2 plasmid (Promega, Fitchburg, WI) was
transiently transfected into NCM460 cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) [17]. Twenty-four hours post-transfection,
cells were treated with λ-carrageenan (1 μg/ml; Sigma Chemical
Company, St. Louis, MO) for 24 h. Promoter activity was measured
utilizing ﬁreﬂy luciferase assay kit (Promega) as described previous-
ly and expressed as relative luciferase units (RLU)/mg protein [17].
Putative transcription factor binding sites in the promoter region
were identiﬁed using TFSEARCH and Motif Search (http://motif.
genome.jp/), as previously described [17].
2.3. BCL10 and phospho-BCL10 by ELISA
A standardized BCL10 ELISA was used to determine the BCL10
content following stimulation by carrageenan, with or without caffeic
acid phenethyl ester (CAPE), an inhibitor of NF-κB activation or MG-
132, a proteasomal inhibitor [4,20,21]. Cells were pre-treated with
CAPE (50 μM×1 h) or MG-132 (20 μM×2 h), and then in combina-
tion with carrageenan (1 μg/ml×24 h). Phospho-BCL10 was detected
by cell-based ELISA using phospho(Ser138)-BCL10 antibody, as previ-
ously described [6,7].
2.4. RelA, RelB and c-Rel binding to BCL10 promoter by
oligonucleotide-based ELISA
Nuclear extracts were prepared from control or carrageenan-
treated NCM460 cells by a nuclear extraction kit (Active Motif,
Carlsbad, CA). Sense and antisense oligonucleotides encompassing
the putative NF-κB binding region in the BCL10 promoter and
corresponding mutated constructs were commercially synthesized.
After being annealed, the double-stranded oligonucleotides [NF-κB
(NF) consensus oligonucleotide: 5′‐GGGACTTTCC-3′; NF-κB Experi-
mental binding site in BCL10 promoter (NFE): 5′‐GGAAACGCCC-3′;
NFE Mutated (NFEM): 5′‐GTCCACGCCC-3′] were coated onto the
wells of 96-well microtiter plates according to the reported proce-
dure [22]. Treated and control nuclear extract samples were added
to the coated wells and incubated for 1 h. NF-κB components (RelA,
RelB or c-Rel) bound to the coated oligonucleotides were captured
by anti-RelA, anti-RelB or anti-c-Rel antibodies and detected by an
anti-rabbit-HRP-conjugated IgG (Active Motif). Color development
was performed with hydrogen peroxide/TMB chromogenic substrate,
and intensity of the developed color proportionately represented the
quantity of NF-κB component in each sample. The sample values
were normalized with the total cell protein determined by protein
assay kit (Pierce, ThermoFisher Scientiﬁc, Rockford, IL).
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(DIG)-non-radioactive gel shift assay
The binding of RelA (p65) to the putative NF-κB binding element
was detected utilizing the non‐radioactive DIG Gel Shift Kit (Roche,
Indianapolis, IN). Nuclear extracts from control or carrageenan-
treated cells were prepared using the nuclear extraction kit (Active
Motif). Recombinant terminal transferase and digoxigenin (DIG)-11-
ddUTP were used to label the 3′ end of the NF-κB oligonucleotide
binding site in the BCL10 promoter (NFE) which differed from the
consensus oligonucleotide for NFκB (NF) and the mutated NF-κB
binding sequence in BCL10 promoter (NFEM). The labeled probe
was incubated with the nuclear extracts with or without competition
by unlabeled oligos, with or without speciﬁc RelA or p50 antibodies,
for analysis of competition, as described previously [7]. Nuclear ex-
tracts and probes were run on a 4% polyacrylamide gel. An alkaline
phosphatase conjugated anti-digoxigenin antibody bound to the
DIG-labeled oligonucleotide–protein complex, and the immobilized
alkaline phosphatase removed a phosphate group from the chemi-
luminescent substrate CSPD, thereby emitting a signal that was
detected and proportionate to the amount of bound NFE.
2.6. Detection of DNA–protein interactions by chromatin
immunoprecipitation (ChIP) assay
ChIP assay was performed utilizing a ChIP assay kit (Active Motif).
Control and carrageenan-treated HT-29 cells were ﬁxed with 1%
formaldehyde for 10 min at room temperature, followed by shearing
of chromatin by sonication. Sheared DNA was incubated with anti-
RelA and anti-RelB antibodies (Active Motif) for 1 h. Protein–DNA
complexes were precipitated by protein A-coupled agarose beads.
After puriﬁcation of the DNA from the immunoprecipitated complexes
by reversal of cross-linking, followed by proteinase K treatment, real-
time RT-PCRwas performed using Brilliant SYBR Green QRT-PCRmas-
ter mix (Stratagene, La Jolla, CA) and Mx3000 (Stratagene) with the
primer pair (forward: 5′‐ACGGAAACGATGCCTTATGA-3′ and reverse:
5′-TCCTTCCCTCTAGGCTCAGG-3′) that encompassed the putative
NF-κB binding element in the BCL10 promoter. Band intensity was
compared between the carrageenan-treated and the control samples
on a 1.5% agarose gel.
2.7. Carrageenan and dextran sulfate sodium (DSS) withdrawal studies
NCM460 and HT-29 cells grown to 60% conﬂuency in 24-well
plates were treated with λ-carrageenan (1 μg/ml) or DSS (1 μg/ml;
Sigma, St. Louis, MO) for 12 h. In selected wells, carrageenan or
DSS treatment was continued for 60 h, with exchange of fresh, car-
rageenan or DSS-containing media every 12 h. In other wells, carra-
geenan or DSS was withdrawn after 12 h, and fresh media, without
carrageenan or DSS was exchanged every 12 h. Samples (cells or
spent media) from all preparations were collected at 12 h intervals.
Spent media were stored at −80 °C for subsequent IL-8 measure-
ment; cells were washed with 1× PBS and stored at −80 °C for
later processing to measure RelA or RelB in the nuclear extracts.
2.8. Statistical analysis
Data are the mean±Standard Deviation (S.D.) of three inde-
pendent biological samples with two technical replicates of each de-
termination, unless stated otherwise. Statistical signiﬁcance was
determined by one-way ANOVA followed by a post-hoc Tukey–
Kramer test for multiple comparisons, unless stated otherwise in
the Results or ﬁgure legends, using Prism or InStat software (Gra-
phPad, Carlsbad, CA). Asterisks represent signiﬁcant differences
compared to control, with * for p≤0.05, ** for p≤0.01, and *** for
p≤0.001.3. Results
3.1. Carrageenan exposure increased BCL10 promoter activity
NCM460 cells, derived from normal colonic epithelial cells, were
exposed to λ-carrageenan (carrageenan 1 μg/ml×24 h) to examine
the effects on BCL10 promoter activity. A 1310 bp fragment of the
5′-untranslated region of the BCL10 gene that has cis elements for
various transcription factors, including NF-κB, was cloned previously
in the pGL2 reporter plasmid [17]. When transiently transfected
into NCM460 cells, the cloned fragment showed 10-fold greater
promoter activity, as compared to pGL2 empty vector control.
Carrageenan treatment for 24 h further increased the BCL10 pro-
moter activity (~2-fold) (Fig. 2A), consistent with previously re-
ported increases in BCL10 expression following carrageenan. The
carrageenan-induced increase in BCL10 protein expression was
completely inhibited when NCM460 cells were pre-incubated with
caffeic acid phenethyl ester (CAPE 50 μM×1 h, then in combination
with carrageenan 1 μg/ml×24 h), an inhibitor of NF-κB nuclear trans-
location (Fig. 2B). In contrast, the carrageenan-induced increase in
phospho-BCL10 level was unaffected (Fig. 2C). In the colorectal ad-
enocarcinoma cell‐line HT-29, a similar decline in BCL10 protein ex-
pression and no change in phospho-BCL10 were demonstrated with
CAPE and with the proteasomal inhibitor MG-132 (20 μM×2 h,
then in combination with λ-carrageenan×24 h) (Fig. 2D, E),
indicating that these effects are not cell-line speciﬁc. These ﬁndings
demonstrate that the enhanced BCL10 expression following carra-
geenan is a transcriptional effect that requires the nuclear translo-
cation of NF-κB.
3.2. Carrageenan increased RelA and RelB binding to BCL10 promoter
3.2.1. Oligonucleotide-based ELISA
The BCL10 promoter construct contains a sequence with high
homology to the established NF-κB consensus sequence that was iden-
tiﬁed as a putative NF-κB binding sequence [17]. By oligonucleotide-
based ELISA, carrageenan exposure signiﬁcantly increased binding of
RelA to the NFE (experimental NF-κB binding site in BCL10 promoter),
as well as to the established NF-κB consensus sequence (NF)
(pb0.001), but not to the mutated sequence (NFEM) in the NCM460
cells (Fig. 3A). Carrageenan treatment also signiﬁcantly increased bind-
ing of RelB to the NFE and NF (pb0.001), but not the NFEM (Fig. 3B).
Carrageenan treatment did not induce c-Rel binding to NF, NFE or
NFEM (Fig. 3C).
3.2.2. Non-radioactive competitive oligonucleotide-protein gel
shift assay
The carrageenan-induced enhancement of NF-κB binding to NFE
was also shown by competitive oligonucleotide-protein gel shift
assay in the NCM460 cells (Fig. 3D, E). Digoxigenin (DIG)-non-ra-
dioactive gel shift assay was performed with NCM460 cell nuclear
extract alone and following exposure of the cells to carrageenan.
The nuclear extract-NFE (protein-oligonucleotide) band intensity
was increased in response to carrageenan treatment, compared to
the untreated control (Lane 3 vs. Lane 2, Fig. 3D). The addition of
RelA antibody or p50 antibody successfully competed for binding
between the endogenous RelA (Lane 4) or p50 (Lane 5) in the
nuclear extract and the labeled oligonucleotide binding site in the
BCL10 promoter (NFE), and eliminated the protein-oligonucleotide
band. In contrast, the IgG negative control had no effect (Lane 6).
Nuclear extract binding to labeled NFE was competed out by
unlabeled NFE oligonucleotide (lane 4, Fig. 3E), but not by the mu-
tated unlabeled oligonucleotide (NFEM) (lane 5). In the antibody
competition assay, the RelA antibody (lane 6) and the p50 antibody
(lane 7) competed out the binding of the endogenous Rel A or p50
in the nuclear extract to labeled NFE, as noted above.
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Fig. 2. Carrageenan enhances BCL10 promoter activity in NCM460 cells. A.When NCM460 cells were transiently transfectedwith the BCL10 promoter construct in the pGL2 vector or with the
empty vector and exposed to carrageenan (1 μg/ml×24 h), promoter activity increased signiﬁcantly. Results are mean±S.D. of ﬁve independent experiments (***pb0.001 vs. control).
B. NCM460 cells were pre-treated with CAPE (50 μM×1 h, then in combination with carrageenan 1 μg/ml×24 h), and BCL10 protein was measured by ELISA in the cell lysate. The
carrageenan-induced increase in BCL10 was inhibited in the presence of CAPE. C. Phospho(Ser138)-BCL10 protein expression in NCM460 cells, as detected by cell-based ELISA, increased
following carrageenan and was unaffected by CAPE. D. In the HT-29 cells, both CAPE and MG-132 (20 μM for 2 h, then in combination with carrageenan 1 μg/ml×24 h) inhibited the
carrageenan-induced increase in BCL10, as detected by ELISA. E. In the HT-29 cells, neither CAPE nor MG-132 affected the carrageenan-induced increase in phospho(Ser138)-BCL10. Results
shown are mean±S.D. of three independent experiments (***pb0.001 vs. control). [CGN= carrageenan; CAPE = caffeic phenethyl ester].
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Chromatin immunoprecipitation (ChIP) assay examined the in
vivo interaction of RelA and RelB proteins with the BCL10 promoter
following carrageenan exposure in the HT-29 cells. The BCL10 pro-
moter had increased interaction with RelA (Fig. 3F) and RelB
(Fig. 3G) in carrageenan-treated cells, compared to control. The spec-
iﬁcity of the ChIP was veriﬁed using control IgG-precipitated chroma-
tin, and no PCR-ampliﬁed product was visible.
3.3. Carrageenan exposure caused prolonged NF-κB activation in
NCM460 and HT-29 cells
Since the function of the NF-κB-BCL10 loop was anticipated to
lead to a prolonged inﬂammatory response following carrageenan
exposure, the duration of the effects of carrageenan stimulation
was tested following carrageenan withdrawal. In the NCM460 cells,
IL-8 secretion in the spent media (Fig. 4A), total cellular BCL10 pro-
tein content (Fig. 4B), and nuclear RelA (Fig. 4C) remained signiﬁ-
cantly elevated compared to control for 24 h after carrageenan
withdrawal. Nuclear RelB (Fig. 4D) remained signiﬁcantly elevated
for 12 h after carrageenan withdrawal. A sustained increase in BCL10
was also demonstrated by Western blot at 36 h which indicates signif-
icantly increased BCL10 protein, compared to untreated control
(Fig. 4E), although less than with continuous carrageenan treatment.
Phospho(Ser138)-BCL10 was markedly increased at 36 h followingcontinuous exposure to carrageenan, as demonstrated by Western
blot (Fig. 4F). When carrageenan was withdrawn after 12 h, the inten-
sity of the band for phospho-BCL10 at 36 hwasmuch reduced. In HT-29
cells, even larger sustained effects were observed followingwithdrawal
of carrageenan thanwere evident in the NCM460 cells (Supplementary
Fig. 1A–D).3.4. DSS treatment did not lead to sustained NF-κB activation
Effects of carrageenan differed from those obtained following ex-
posure to dextran sodium sulfate (DSS), the sulfated polysaccharide
that is very commonly used to cause inﬂammation in cell-based and
animal experiments. DSS (1 μg/ml×24 h) increased RelA, but not
RelB in NCM460 cells (Fig. 5A). Withdrawal experiments using
DSS in the NCM460 and HT-29 cells showed that DSS stimulation
did not produce sustained increases in RelA or IL-8. Treatment
with DSS (1 μg/ml) for 12 h signiﬁcantly increased IL-8 secretion
(Fig. 5B) and nuclear RelA (Fig. 5C), compared to control. However,
upon DSS withdrawal, IL-8 and RelA levels declined to the control
levels by 24 h, indicating that the inﬂammatory response was not
sustained. RelB did not increase following exposure to DSS in the
NCM460 cells (Fig. 5D). Similar lack of sustained increases in IL-8
and RelA was demonstrated in the HT-29 cells following exposure
to DSS (Supplementary Fig. 2A–B).
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Fig. 3. Oligonucleotide-protein assays demonstrate binding to the NF-κB binding element in the BCL10 promoter. The double-stranded annealed nucleotides corresponding to
the established NF-κB consensus sequence (NF), the putative, experimental NF-κB binding element in the BCL10 promoter (NFE), or its mutated version (NFEM) were coated
onto the wells of microtiter plates. A. In the NCM460 cells, binding of RelA to the NF-κB consensus sequence (NF) and NF-κB binding element in the BCL10 promoter (NFE)
was increased following exposure to carrageenan, whereas binding to the mutated sequence (NFEM) was unaffected. B. Similarly, binding of RelB to NF and NFE was increased
after carrageenan, but binding to NFEM was unaffected. C. No increase in binding of c-Rel to either NF, NFE or NFEM was detected following carrageenan. D. Digoxigenin (DIG)-
non-radioactive gel shift assay was performed with untreated NCM460 cell nuclear extract and following exposure of the cells to carrageenan. Lane 1: No nuclear extract; Lane
2: nuclear extract and labeled NFE; Lane 3: carrageenan-treated nuclear extract and NFE; Lane 4: carrageenan-treated nuclear extract, NFE and RelA antibody; Lane 5;
carrageenan-treated nuclear extract, NFE, and p50 antibody, and Lane 6: carrageenan-treated nuclear extract, NFE, and IgG control. Studies demonstrate increase in the
oligonucleotide-protein band following carrageenan (Lane 3 vs. Lane 2). Exogenous RelA and p50 antibodies compete for binding between the endogenous RelA (Lane 4)
or p50 (Lane 5) in the nuclear extract and the oligonucleotide binding site in the BCL10 promoter (NFE), eliminating the protein-oligonucleotide band. In contrast, IgG
has no effect on the binding of the nuclear extract and the labeled NFE (Lane 6). E. Digoxigenin (DIG)-non-radioactive gel shift assay showed carrageenan enhancement
of RelA binding to the NF-κB binding element in the BCL10 promoter. Competition studies with cold (unlabeled) NFE or cold (unlabeled) and mutated NFEM or with RelA
and p50 antibodies were performed to conﬁrm the speciﬁcity of the protein-DNA interaction between RelA or p50 with the NF-κB binding site in the BCL10 promoter. Lane
1: No nuclear extract; Lane 2: control nuclear extract and labeled NFE; Lane 3. carrageenan-treated nuclear extract and NFE; Lane 4: competition by cold NFE; Lane 5: compe-
tition by cold NFEM; Lane 6: competition by RelA antibody; Lane 7: competition by p50 antibody. A representative blot of 4 independent experiments with similar results is
shown. F, G. Increased binding of RelA and RelB to the BCL10 promoter by chromatin immunoprecipitation (ChIP) assay following carrageenan exposure. Control or carrageenan
(1 μg/ml×24 h) treated NCM460 cells were ﬁxed with formaldehyde, and chromatin prepared from these cells was sheared, and then immunoprecipitated with anti-RelA, anti-
RelB antibody or with control IgG. Speciﬁc primers were used to amplify the promoter region containing the NF-κB binding element in the human BCL10 promoter. Ampliﬁed
products were resolved on 1.5% agarose gel and indicate marked increase following carrageenan vs. control. [Cn = control; CGN = lambda-carrageenan; NF = NF-κB consensus
sequence; NFE = experimental NF-κB binding element in the BCL10 promoter; NFEM = mutated NF-κB binding element in the BCL10 promoter].
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Previous reports have presented three pathways by which expo-
sure to the common food additive carrageenan stimulates inﬂamma-
tion in human colonic epithelial cells (Fig. 1) [4–8]. These include
pathways initiated by interaction of carrageenan with the toll-likereceptor (TLR)-4, requiring MyD88, IRAK, and BCL10. The canonical
pathway of NF-κB activation involves BCL10 interaction with IKKγ,
the regulatory subunit of the IKK signalosome, leading to IKKγ
ubiquitination, IKKβ phosphorylation of IκBα, and nuclear transloca-
tion of NF-κB RelA (p65) and p50. Alternatively, as in the non-
canonical pathway of NF-κB activation, phospho-BCL10 interacts
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Fig. 4. Sustained increases in IL-8, BCL10, RelA, and RelB following carrageenan exposure in NCM460 and HT-29 cells. NCM460 cells were either exposed to carrageenan
continuously for 60 h with media exchange and replenishment of carrageenan every 12 h, exposed to carrageenan for only an initial 12 h period with media exchange
every 12 h, or not exposed to carrageenan at all with media exchange every 12 h. Statistical signiﬁcance was determined by one-way ANOVA with Tukey–Kramer post-test.
A. In the NCM460 cells, when compared to untreated controls, IL-8 remained signiﬁcantly elevated at 24 (pb0.001) and 36 h (pb0.05) in the spent media of the cells treated
for only 12 h. B. Total cellular BCL10 remained signiﬁcantly increased at 24 (pb0.001) and 36 (pb0.001) hours, following withdrawal of carrageenan after 12 h. C. RelA
remained signiﬁcantly increased in the nuclear lysates of the NCM460 cells at 24 (pb0.001) and 36 (pb0.001) hours, following 12 h of carrageenan exposure. D. RelB remained
signiﬁcantly increased at 24 (pb0.01) hours in the NCM460 cells following withdrawal of carrageenan after 12 h. E. Western blot demonstrates increase in BCL10 protein
at 36 h following withdrawal of carrageenan after 12 h. Continued exposure to carrageenan leads to more intense staining. Densitometry conﬁrms the visual impression.
[CGN = carrageenan]. F. Western blot demonstrates marked increase in the band intensity of phospho-BCL10 at 36 h upon continuous exposure to carrageenan, and a
much smaller response when carrageenan was withdrawn after 12 h.
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IKKα and the nuclear translocation of RelB and p52. In addition to the
TLR4-BCL10 mediated pathways, carrageenan exposure stimulates a
reactive oxygen species (ROS)-mediated pathway, in which phospho-
Hsp27 interacts with the IKK signalosome, leading to the phosphoryla-
tion of IκBα and the nuclear translocation of NF-κB. To these pathways,
we now add a feedback loop, by which NF-κB binding to the BCL10 pro-
moter leads to increased production of BCL10, which can thereby con-
tinue activation of the inﬂammatory process.
The caspase recruitment domain (CARD)-containing protein BCL10
has previously been implicated in sustained inﬂammatory processes
in lymphocytes, since translocations involving BCL10 are of etio-
logic signiﬁcance in the development of mucosa-associated lymphoid
tissue (MALT) lymphomas [11,12]. TheMALT lymphomas,ﬁrst described
in 1983, are the third most common subtype of non-Hodgkin's Lympho-
ma. They arise in a wide range of sites, including most commonly the
stomach (~70%), the lung (~14%), then ocular adnexa, thyroid, and the
small intestine [23–25]. Majority of the gastric MALT lymphomas are
attributable to Helicobacter pylori infections, and are amenable to cure
by eradication of the infection. The association of reciprocal chro-
mosomal translocations involving BCL10 [t(1;14)(p22;q32)] or MALT1
[t(11;18)(q21;q21) and t(14;18)(q32;q21)] with MALT lymphomas
that are not attributable to H. pylori indicates an overlap between the
molecular mechanisms that are manifestations of infection- and
inﬂammation-associated malignancies.Carrageenan due to its unique chemical structure stimulates in-
nate immune responses and evokes sustained activation of NF-κB
and BCL10. Previously, we reported that NF-κB activation in re-
sponse to DSS treatment was mediated via reactive oxygen species
and Hsp27, and did not involve TLR4 or BCL10, since BCL10 si-
lencing had no impact on the responses to DSS, DSS exposure
did not increase BCL10, and MyD88 and TLR4 were not required
for DSS effects [26]. In the current study, inﬂammatory responses
are not prolonged following withdrawal of DSS, consistent with
observed effects in animal models [27]. The difference in the in-
ﬂammatory mechanisms between carrageenan and DSS, both of
which are highly sulfated polysaccharides, but vary in their spe-
ciﬁc hexoses and in their glycosidic bonds, supports the essential
role of the unique chemical structure of carrageenan, involving
its unusual alpha-1,3-galactosidic bond, in activation of an innate
immune response [28,29]. In contrast, DSS, which is not used as
a food additive, but predictably causes inﬂammation, is com-
posed of glucose residues, linked predominantly in alpha-1,6-
bonds [30].
The post-translational modiﬁcations of BCL10 may modulate the
effects of speciﬁc inﬂammatory signals, and BCL10 may serve a crit-
ical function in the downstream regulation of different inputs, such
as those from carrageenan, lipopolysaccharide, platelet-activating
factor, angiotensin II, and lysophosphatidic acid [6,7,13–18]. The
phosphorylation of BCL10 Ser138 is required for phosphorylation
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Fig. 5. DSS-induced increase in IL-8 and RelA (p65) are not sustained upon DSS withdrawal in NCM460 or HT-29 cells. A. DSS exposure produced no increase in RelB in the NCM460
cells. NCM460 cells were initially exposed to DSS (1 μg/ml) for 12 h. This was followed by either replenishment with fresh DSS‐containing media every 12 h, or with media without
DSS. Samples (spent media or cells) were harvested every 12 h. B. IL-8 declined to untreated level by 24 h in the NCM460 cells. C. RelA declined to untreated level by 24 h in the
NCM460 cells. [DSS = dextran sulfate sodium]. D. RelB did not increase following exposure to DSS in the NCM460 cells.
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was not affected by proteasomal inhibition by MG-132 or by
CAPE, indicating that BCL10 phosphorylation occurs indepen-
dently of NF-κB nuclear translocation, in contrast to BCL10 ex-
pression [6,7,18,21]. The study ﬁnding that the RelB activation
is sustained for a shorter interval than the RelA activation sug-
gests that another process, likely involving the phosphorylation
of NIK, BCL10, or IKKα, is also required to prolong the activation
of the non-canonical pathway.
Exposure of cells to inﬂammatory stimuli results in rapid phos-
phorylation and degradation of IκBα and subsequent translocation
of NF-κB to the nucleus. These events enable prompt cellular re-
sponse in the absence of de novo protein synthesis [31,32]. Given
the central role of NF-κB in the pathogenesis and maintenance of
chronic inﬂammatory states, examination of mechanisms that con-
tribute to the prolonged activation of NF-κB is of considerable rel-
evance to human disease. In the current report, carrageenan
exposure for 12 h caused sustained RelA activation, IL-8 produc-
tion, and BCL10 protein level for 48 h. Since up‐regulation of
BCL10 expression results from NF-κB activation, and NF-κB activa-
tion following carrageenan exposure involves BCL10, a positive
feedback loop involving BCL10 and NF-κB that causes prolonged
activation of NF-κB in response to carrageenan may have clinical
signiﬁcance, leading to extended inﬂammation in intestinal epi-
thelial cells. The relationship between infectious or inﬂammatory
processes and malignancy, such as H. pylori and gastric cancer,
human papillomavirus and cervical cancer, or ulcerative colitis
and colorectal carcinoma, is also of interest, since therapeutic in-
terventions with anti-microbial and anti-inﬂammatory agents
that retard inﬂammation may impact upon neoplastic transforma-
tion. Identiﬁcation of speciﬁc transcriptional regulatory mecha-
nisms, such as this NF-κB-BCL10 loop that is set in motion bycarrageenan exposure, may contribute to improved understanding
of the origins of malignancy, as well as of chronic inﬂammation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.05.001.Acknowledgements
Supported by the Department of Veterans Affairs and the NIDDK
(R01-DK54016, R01-DK81858 and PO1-DK67887).References
[1] J.K. Tobacman, Environ. Health Perspect. 109 (2001) 983–994.
[2] Encyclopædia Britannica, “algae” Encyclopædia Britannica Online, Encyclopædia
Britannica, 2010. Web. 22 Jan 2011, http://search.eb.com/eb.article-31714.
[3] J. West, K.N. Miller, California's living marine resources: a status report.
Agarophytes and carrageenophytes, California Department of Fish and Game,
2001, pp. 286–287.
[4] A. Borthakur, S. Bhattacharyya, P.K. Dudeja, J.K. Tobacman, Am. J. Physiol. Gas-
trointest. Liver Physiol. 292 (2007) G829–G838.
[5] S. Bhattacharyya, R. Gill, M.L. Chen, F. Zhang, R.J. Linhardt, P.K. Dudeja, J.K.
Tobacman, J. Biol. Chem. 283 (2008) 10550–10558.
[6] S. Bhattacharyya, A. Borthakur, A.N. Anbazhagan, S. Katyal, P.K. Dudeja, J.K.
Tobacman, Am. J. Physiol. Gastrointest. Liver Physiol. 301 (2011) G475–G486.
[7] S. Bhattacharyya, A. Borthakur, S. Tyagi, R. Gill, M.L. Chen, P.K. Dudeja, J.K.
Tobacman, J. Biol. Chem. 285 (2010) 522–530.
[8] S. Bhattacharyya, P.K. Dudeja, J.K. Tobacman, Biochim. Biophys. Acta 1780 (2008)
973–982.
[9] S. Bhattacharyya, I. O-Sullivan, S. Katyal, T. Unterman, J.K. Tobacman, Diabetologia
55 (2012) 194–203.
[10] H. Shi, M.V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, J.S. Flier, J. Clin. Invest. 116
(2006) 3015–3025.
[11] T.G. Willis, D.M. Jadayel, M.Q. Du, H. Peng, A.R. Perry, M. Abdul-Rauf, H. Price, L.
Karran, O. Majekodunmi, I. Wlodarska, L. Pan, T. Crook, R. Hamoudi, P.G.
Isaacson, J.F. Dyer, Cell 96 (1999) 35–45.
[12] Q. Zhang, R. Siebert, M. Yan, B. Hinzmann, X. Cui, L. Xue, K.M. Rakestraw, C.W.
Naeve, G. Beckmann, D.D. Weisenburger, W.G. Sanger, H. Nowotny, M. Vesely,
1307A. Borthakur et al. / Biochimica et Biophysica Acta 1822 (2012) 1300–1307E. Callet-Bauchu, G. Salles, V.M. Dixit, A. Rosenthal, B. Schlegelberger, S.W. Morris,
Nat. Genet. 22 (1999) 63–68.
[13] S. Bhattacharyya, A. Borthakur, N. Pant, P.K. Dudeja, J.K. Tobacman, Am. J. Physiol.
Gastrointest. Liver Physiol. 293 (2007) G429–G437.
[14] D. Wang, Y. You, P.C. Lin, L. Xue, S.W. Morris, H. Zeng, R. Wen, X. Lin, Proc. Natl.
Acad. Sci. U. S. A. 104 (2007) 145–150.
[15] L.M. McAllister-Lucas, J. Ruland, K. Siu, X. Jin, S. Gu, D.S. Kim, P. Kuffa, D. Kohrt,
T.W. Mak, G. Nuñez, P.C. Lucas, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 139–144.
[16] S. Klemm, S. Zimmermann, C. Peschel, T.W. Mak, J. Ruland, Proc. Natl. Acad. Sci.
U. S. A. 104 (2007) 134–138.
[17] A. Borthakur, S. Bhattacharyya, W. Alrefai, J.K. Tobacman, K. Ramaswamy, P.K.
Dudeja, Inﬂamm. Bowel Dis. 16 (2010) 594–603.
[18] S. Bhattacharyya, A. Borthakur, P.K. Dudeja, J.K. Tobacman, Exp. Cell Res. 316
(2010) 3317–3327.
[19] M.P. Moyer, L.A. Manzano, R.L. Merriman, J.S. Stauffer, L.R. Tanzer, In Vitro Cell.
Dev. Biol. Anim. 32 (1996) 315–317.
[20] S. Bhattacharyya, N. Pant, P.K. Dudeja, J.K. Tobacman, J. Immunoassay Immuno-
chem. 28 (2007) 173–188.
[21] S. Bhattacharyya, P.K. Dudeja, J.K. Tobacman, Am. J. Physiol. Gastrointest. Liver
Physiol. 293 (2) (2007) G429–G437.[22] A. Zaﬁropoulos, G. Hatzidakis, L. Mavrogiannis, A. Klinakis, M. Kandilogiannaki, E.
Krambovitis, Biotechniques 23 (1997) 1104–1109.
[23] P. Isaacson, D.H. Wright, Cancer 52 (1983) 1410–1416.
[24] X. Sagaert, E. Van Cutsem, G. De Hertogh, K. Geboes, T. Tousseyn, Nat. Rev.
Gastroenterol. Hepatol. 7 (2010) 336–346.
[25] http://www.cancer.gov/cancertopics/factsheet/Risk/h-pylori-cancer.
[26] S. Bhattacharyya, P.K. Dudeja, J.K. Tobacman, Inﬂamm. Bowel Dis. 15 (2009)
673–683.
[27] Y. Yan, V. Kolachala, G. Dalmasso, H. Nguyen, H. Laroui, S.V. Sitaraman, D. Merlin,
PLoS One 4 (2009) e6073.
[28] S. Bhattacharyya, H. Liu, Z. Zhang, M. Jam, P.K. Dudeja, G. Michel, R.J. Linhardt, J.K.
Tobacman, J. Nutr. Biochem. 21 (2009) 906–913.
[29] B.A. Macher, U. Galili, Biochim. Biophys. Acta 1780 (2008) 75–88.
[30] http://www.gelifesciences.com/aptrix/upp00919.nsf/Content/A7BB06EF3C4EEE8EC12
57628001CEC60/$ﬁle/18115175AA.pdf.
[31] A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P.M. Humpert, J. Chen,
M. Hong, T. Luther, T. Henle, I. Klöting, M. Morcos, M. Hofmann, H. Tritschler, B.
Weigle, M. Kasper, M. Smith, G. Perry, A.M. Schmidt, D.M. Stern, H.U. Häring, E.
Schleicher, P.P. Nawroth, Diabetes 50 (2001) 2792–2808.
[32] P.J. Barnes, M. Karin, N. Engl. J. Med. 336 (1997) 1066–1071.
